Table 1.
Characteristics of studies included in the quantitative synthesis (meta-analysis).
| First Author and Reference | Year | Disease Type | Ethnicity | Country | Study Design | Age (male/female) |
Subject Type | Sample Size (case/control) |
HWE | Score |
|---|---|---|---|---|---|---|---|---|---|---|
| Abazis-Stambulieh19 | 2007 | MM | European | Greece | C/Cc | 65 (42–80)/65.7 (40–85) | C-heathy | 74/160 | Yes | 10 |
| Alves20 | 2021 | ALL | Mixed | Brazil | C/Cc | 12 (14–17)/38 (26–52) | C-healthy/relapse | 158/192 | Yes | 11 |
| Ennas21 | 2008 | CLL | European | Italy | C/Cc | 57.9 ± 12.5/56.5 ± 13.2 | C-healthy | 40/112 | Yes | 10 |
| Hoeft I22 | 2008 | NHL | European | Germany | C/Cc | 56.1 (Nos) | C-healthy | 640/658 | Yes | 14 |
| Hoeft II22 | 2008 | HL | European | Germany | C/Cc | 56.1 (Nos) | C-Healthy | 105/658 | Yes | 14 |
| Sarani23 | 2021 | NHL | Caucasian | Iran | C/Cc | 20–90/21–75 | C-healthy | 151/165 | No | 9 |
| Wang24 | 2017 | AML | Asian | China | C/Cc | 48 (16–89) | C-healthy/CCRS (cytogenetics risk stratification)/refractory/age/gender/bone marrow blast | 383/300 | Yes | 10 |
| Yin25 | 2016 | MDS | Asian | China | C/Cc | 56 (16–95)/42 (17–85) | C-healthy/Age/gender/hemogram change | 160/96 | Yes | 11 |
| Zhang26 | 2017 | CML | Asian | China | C/Cc | 47 (16–81)/45 (21–83) | C-healthy/risk stratification score/BCR-ABL response | 267/344 | Yes | 10 |
| Zhao27 | 2017 | HL | Asian | China | C/Cc | 54 (13–85)/48 (21–85) | C-healthy | 390/385 | Yes | 10 |
| Zhao27 | 2018 | MM | Asian | China | C/Cc | 60 (25–89)/55 (26–90) | C-healthy/age/gender/classification/bone damaged/hemogram change/BM myeloma cell | 355/350 | Yes | 11 |
| Zhou28 | 2020 | MPN | Asian | China | C/Cc | 59 (16–84)/55 (16–88) | C-healthy | 269/291 | Yes | 11 |
MM: multiple myeloma; ALL: acute lymphoblastic leukemia; CLL: chronic lymphocytic leukemia; NHL: non-Hodgkin lymphoma; HL: Hodgkin lymphoma; AML: acute myeloid leukemia; MDS: myelodysplastic syndrome; CML: chronic myeloid leukemia; MPN: Philadelphia chromosome-negative myeloproliferative neoplasm.
C case, Cc control, HWE Hardy–Weinberg equilibrium.
NOS: not otherwise specified.